CING – cingulate inc. (US:NASDAQ)
Stock Stats
News
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
Cingulate Inc. (NASDAQ: CING) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025 [Yahoo! Finance]
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
Form 10-K Cingulate Inc. For: Dec 31
Form 8-K Cingulate Inc. For: Mar 26
Form 8-K Cingulate Inc. For: Mar 04
Form 4 Cingulate Inc. For: Feb 18 Filed by: Silva Raul R.
Form 4 Cingulate Inc. For: Feb 18 Filed by: Callahan Jennifer L.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.